Phase 1 Lung Cancer Trial, Not Yet Recruiting NCT06585059 Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Condition: Lung Cancer
Back to Lung Cancer

Phase 1 Lung Cancer Trial, Not Yet Recruiting

NCT06585059
Not Yet Recruiting Phase 1

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged between 18 and 75 years, with a good general activity level and an expected survival of more than 3 months.
  • People who have been diagnosed with locally advanced or metastatic non-small cell lung cancer (a type of lung cancer that has spread or cannot be removed by surgery), confirmed by a tissue or cell sample.
  • People whose major organs (such as heart, liver, and kidneys) are working well.
  • Women who are not pregnant (confirmed by a blood test within 7 days before starting the trial) and not breastfeeding; both women and men who could potentially have children must agree to use contraception throughout the study and for 6 months after it ends.
  • People who are willing to take part voluntarily, have signed a consent form, and are expected to follow the study requirements.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have had another type of cancer within the past 5 years, at the same time as their current diagnosis.
  • People still experiencing side effects above a mild level from any previous cancer treatment.
  • People who have had major surgery, a biopsy, or a significant injury within 28 days before starting the trial.
  • People with wounds or broken bones that have not healed over a long period.
  • People who have had a stroke, mini-stroke, blood clot in a deep vein, or a blood clot in the lungs within the past 6 months.
  • People with a history of misusing mind-altering substances and who are unable to stop, or people with a diagnosed mental health disorder.
  • People with any serious or uncontrolled illness or medical condition.
  • People who have received a live vaccine within 2 weeks before starting the trial, or who plan to receive a live vaccine during the study.
  • People with a history of unexplained severe allergies, or who have had a reaction to monoclonal antibody medicines, human immunoglobulin products, or to the study drug (TQB2928) or its ingredients.
  • People whom the study doctor considers unsuitable for the trial due to other health conditions or concerns that could affect their safety or their ability to complete the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026

Contact this trial

Phone: 020-87343458

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 1
Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
1 September 2024
Est. completion
1 December 2025

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Phase II recommended combination doses (RP2CD); Objective Response Rate (ORR); Duration of Response (DOR); Progression-free survival (PFS); Time to Progression

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov